Drug Approval | April 15, 2022
Lupin receives approval from USFDA for Desvenlafaxine extended-release tablets 25 mg
The product will be manufactured at Lupin’s facility in Goa, India
The product will be manufactured at Lupin’s facility in Goa, India
Lidocaine and Prilocaine Cream USP, 2.5%/2.5% has an estimated market size of US $ 29 million for twelve months ending Dec. 2021 according to IQVIA
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Pradaxa Capsules of Boehringer lngelheim
Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 clinical trial in adult patients with moderate-to-severe Covid-19
Aveir VR is specifically designed to be retrieved when therapy needs to evolve or the device needs to be replaced
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
Recommendation is based on pivotal data from the phase III POLARIX study
The product will be manufactured at Lupin’s facility in Goa, India
Subscribe To Our Newsletter & Stay Updated
